Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

CROSS-REACTIVE NEUTRALIZING ANTIBODY AGAINST PANDEMIC 2009 H1N1 INFLUENZA A VIRUS IN INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS PEDIATRIC INFECTIOUS DISEASE JOURNAL Hong, D. K., Tremoulet, A. H., Burns, J. C., Lewis, D. B. 2011; 30 (1): 67-69

Abstract

Prepandemic intravenous immunoglobulin (IVIG) and sera from Kawasaki disease patients treated with this IVIG were analyzed for 2009 H1N1-specific microneutralization and hemagglutination inhibition antibodies. All 6 different IVIG preparations tested had significant levels of cross-reactive-specific antibody at a concentration of 2.0 g/dL of immunoglobulin. Sera from 18 of 19 Kawasaki disease patients had significant increases of cross-reactive-specific antibody after 2.0 g/kg of prepandemic IVIG. These results suggest a role for adjunctive IVIG therapy for severe and/or drug-resistant 2009 H1N1 virus and other highly antigenically drifted influenza strains, particularly in the immunocompromised.

View details for DOI 10.1097/INF.0b013e3181f127be

View details for PubMedID 20724956